Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
Giant pharma companies are not the right owners of ultra-rare disease orphan drugs. The associated revenue streams are simply too small. ETON can acquire and develop these drugs, better serving patients and investors. The model is already working well. ETON is able to execute on straightforward product improvements, and has the focus to educate specialist doctors on the need for these rare drugs.
Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Madison Elsaadi - B. Riley Swayampakula Ramakanth - H.C.
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.03 per share a year ago.
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q4 2024 Earnings Conference Call March 18, 2025 10:00 AM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Ipek Trinkaus - Chief Commercial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Madison Elsaadi - B. Riley Operator Good day, and thank you for standing by.
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.
Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going
Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength?
Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'
Eton Pharmaceuticals (ETON) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Chase Knickerbocker – Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised, this call is being recorded at the company's request.
